English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chemerin-derived peptide Val 66 -Pro 85  (p4) restricts the growth of a variety of skin-associated bacteria, including methicillin-resistant  Staphylococcus aureus  (MRSA). To better understand the antimicrobial potential of chemerin peptide, we compared p4 activity against MRSA  in vitro  to cathelicidin LL-37, one of the key endogenous peptides implicated in controlling the growth of  S. aureus . The efficacy of p4 was also validated in relevant experimental models of skin pathology, such as topical skin infection with community-acquired MRSA, and in the context of skin inflammatory diseases commonly associated with colonization with  S. aureus , such as atopic dermatitis (AD). We showed that p4 collaborates additively with LL-37 in inhibiting the growth of  S. aureus , including MRSA, and that p4 was effective  in vivo  in reducing MRSA burden. p4 was also effective in reducing levels of skin-infiltrating leukocytes in  S. aureus -infected AD-like skin. Taken together, our data suggest that p4 is effective in limiting  S. aureus  and, in particular, MRSA skin infection.

Chemerin-Derived Peptide Val66-Pro85 Is Effective in Limiting Methicillin-Resistant S. aureus Skin Infection